Alzamend Neuro, Inc. (NASDAQ:ALZN – Get Free Report)’s stock price shot up 14.2% on Friday . The stock traded as high as $1.75 and last traded at $1.69. 52,491 shares changed hands during trading, an increase of 241% from the average session volume of 15,391 shares. The stock had previously closed at $1.48.
Alzamend Neuro Stock Performance
The firm has a market cap of $10.93 million, a price-to-earnings ratio of -0.70 and a beta of 0.14. The company’s fifty day moving average is $3.24 and its two-hundred day moving average is $5.90.
Hedge Funds Weigh In On Alzamend Neuro
About Alzamend Neuro
Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
- Five stocks we like better than Alzamend Neuro
- What Are MATANA Stocks?
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- How to Buy Bitcoin Stock: 3 Easy Ways to Do It
- MarketBeat Week in Review – 11/13 – 11/17
- What is Put Option Volume?
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for Alzamend Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alzamend Neuro and related companies with MarketBeat.com's FREE daily email newsletter.